報價延遲最少15分鐘:2025/07/20 17:00 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.35 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.14/-2.63
|
|
企業價值
59.74M
|
| 資產負債 |
|
每股賬面淨值
2.81
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 17:00 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it isobserved their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45. |
